Thanks to the collaboration between teams from the AP-HP, the MedTech METAFORA biosystems, the Institute of Molecular Genetics of Montpellier, Cerba Healthcare, and more than 30 investigating centers coordinated by Prof. Fanny Mochel at Paris Brain Institute, a reliable and rapid blood test now enables early diagnosis of Glut1 deficiency syndrome, or De Vivo disease – a rare and yet treatable neurometabolic condition. A multicenter clinical study has validated its performance, the results of which have just been published in Neurology. Given the expected patient benefits, the French National Authority for Health now recommends its reimbursement by health insurance companies.
Thanks to the collaboration between teams from the AP-HP, the MedTech METAFORA biosystems, the Institute of Molecular Genetics of Montpellier, Cerba Healthcare, and more than 30 investigating centers coordinated by Prof. Fanny Mochel at Paris Brain Institute, a reliable and rapid blood test now enables early diagnosis of Glut1 deficiency syndrome, or De Vivo disease – a rare and yet treatable neurometabolic condition. A multicenter clinical study has validated its performance, the results of which have just been published in Neurology. Given the expected patient benefits, the French National Authority for Health now recommends its reimbursement by health insurance companies.
Biophytis has Filed with the French National Authority for Health (HAS) an Application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19 saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / May 26, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the